$THAR
Tharimmune, Inc. Stock $thar

$thar Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223007977 Filed on March 16, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.667M	$1.083M	$4.604M
YoY Change	59.75%	659.63%	237.2%
% of Gross Profit
Research & Development	$1.048M	$683.2K	$2.278M
YoY Change	240.34%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.714M	$1.766M	$6.882M
YoY Change	100.89%	1638.79%
Operating Profit	-$2.700M		-$6.900M
YoY Change	99.83%		115.09%
Interest Expense	$6.138K	$0.00	$1.591M
YoY Change	-100.39%	-100.0%	-291.42%
% of Operating Profit
Other Income/Expense, Net	$26.11K	$0.00	-$1.591M
YoY Change		-100.0%	-186.83%
Pretax Income	-$2.688M	-$1.766M	-$8.473M
YoY Change	-8.64%	-172.01%	283.99%
Income Tax
% Of Pretax Income
Net Earnings	-$2.688M	-$1.766M	-$8.473M
YoY Change	-8.64%	-172.01%	283.99%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.23		-$0.75
Diluted Earnings Per Share	-$0.23	-$0.15	-$0.75
COMMON SHARES
Basic Shares Outstanding	11.51M shares	11.53M shares	11.32M shares
Diluted Shares Outstanding	460.6K shares		452.7K shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.569M	$6.511M	$6.511M
YoY Change	-67.91%	149224.08%	149224.08%
Cash & Equivalents	$3.569M	$6.511M
Short-Term Investments
Other Short-Term Assets	$1.153M	$178.1K	$178.1K
YoY Change	394.35%	-71.15%	-71.15%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.722M	$6.689M	$6.689M
YoY Change	-58.42%	975.9%	975.9%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$4.722M	$6.689M	$6.689M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$4.722M	$6.689M	$6.689M
YoY Change	-58.42%	975.9%	975.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$719.0K	$954.5K	$954.5K
YoY Change	20.34%	-34.76%	-34.76%
Accrued Expenses	$242.2K	$190.5K	$190.5K
YoY Change	10.66%	-40.15%	-61.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$1.521M	$1.145M	$1.145M
YoY Change	49.67%	-74.75%	-74.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.521M	$1.145M	$1.145M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.521M	$1.145M	$1.145M
YoY Change	49.67%	-78.42%	-78.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.10M	-$15.40M
YoY Change		122.83%
Common Stock	$1.160K	$1.160K
YoY Change		82.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$69.97K	$69.97K
YoY Change
Treasury Stock Shares		90.83K shares
Shareholders Equity	$3.201M	$5.544M	$5.544M
YoY Change
Total Liabilities & Shareholders Equity	$4.722M	$6.689M	$6.689M
YoY Change	-58.42%	975.9%	975.9%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.688M	-$1.766M	-$8.473M
YoY Change	-8.64%	-172.01%	283.99%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.500M	-$1.064M	-$6.600M
YoY Change	74.4%	13767.93%	507.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$13.65M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$523.4K	-22.46K	$13.06M
YoY Change	-96.01%	-32.06%	1353.59%
NET CHANGE
Cash From Operating Activities	-$3.500M	-1.064M	-$6.600M
Cash From Investing Activities
Cash From Financing Activities	$523.4K	-22.46K	$13.06M
Net Change In Cash	-$2.941M	-1.086M	$6.506M
YoY Change		2566.66%	-3570.15%
FREE CASH FLOW
Cash From Operating Activities	-$3.500M	-$1.064M	-$6.600M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001861657
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2022Q4	HILS	Redemption Liability Current RedemptionLiabilityCurrent		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability		usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2021	HILS	Interest And Original Issuance Discount On Promissory Notes InterestAndOriginalIssuanceDiscountOnPromissoryNotes		usd
CY2022	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability		usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2021	us-gaap	Notes Issued1 NotesIssued1		usd
CY2021	us-gaap	Notes Reduction NotesReduction		usd
CY2022	HILS	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts		usd
CY2022	HILS	Deferred Offering Costs Reclassified Against Common Stock And Additional Paidin Capital Upon Initial Public Offering DeferredOfferingCostsReclassifiedAgainstCommonStockAndAdditionalPaidinCapitalUponInitialPublicOffering		usd
CY2022Q4	HILS	Deferred Tax Assets Tax Deferred Expense Accrued Expenses And Other DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41210
CY2022	dei	Entity Registrant Name EntityRegistrantName	HILLSTREAM BIOPHARMA, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2642541
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Route 22 East
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2000
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
CY2022	dei	City Area Code CityAreaCode	(908)
CY2022	dei	Local Phone Number LocalPhoneNumber	955-3140
CY2022	dei	Security12b Title Security12bTitle	Common stock, $0.0001 par value
CY2022	dei	Trading Symbol TradingSymbol	HILS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	5600418	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11514144	shares
CY2022	dei	Auditor Firm AuditorFirmId	199
CY2022	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C.
CY2022	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2022Q4	us-gaap	Cash Cash	6510534	usd
CY2021Q4	us-gaap	Cash Cash	4356	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	178094	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	70670	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	546651	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6688628	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	621677	usd
CY2022Q4	us-gaap	Assets Assets	6688628	usd
CY2021Q4	us-gaap	Assets Assets	621677	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	954505	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1463059	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	179621	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	200000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	190468	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	318223	usd
CY2021Q4	HILS	Redemption Liability Current RedemptionLiabilityCurrent	980233	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1392544	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1144973	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4533680	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	772899	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1144973	usd
CY2021Q4	us-gaap	Liabilities Liabilities	5306579	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11604970	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6357314	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11514144	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6357314	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1160	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	636	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20996892	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2225712	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15384432	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6911250	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	90826	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	69965	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5543655	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4684902	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6688628	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	621677	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2278424	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1842803	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4603514	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1365214	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	6881938	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	3208017	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6881938	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3208017	usd
CY2022	us-gaap	Interest Expense InterestExpense	1591244	usd
CY2021	us-gaap	Interest Expense InterestExpense	831277	usd
CY2021	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability	-1832651	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1591244	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1001374	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8473182	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2206643	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11316804	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6357314	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-3717528	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2206643	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1239269	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4684902	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8473182	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24389	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	800696	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12945082	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12945082	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4901537	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	69965	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5543655	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8473182	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2206643	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1569003	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	666566	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	800696	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1239269	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	100000	usd
CY2022	HILS	Interest And Original Issuance Discount On Promissory Notes InterestAndOriginalIssuanceDiscountOnPromissoryNotes	14645	usd
CY2021	HILS	Change In Fair Value Of Redemption Liability ChangeInFairValueOfRedemptionLiability	-1832651	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	107424	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-32276	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-141170	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	580847	usd
CY2022	HILS	Increase Decrease In Interest Payable IncreaseDecreaseInInterestPayable	7237	usd
CY2021	HILS	Increase Decrease In Interest Payable IncreaseDecreaseInInterestPayable	164646	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-200000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-127755	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	269446	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6557950	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1086244	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24389	usd
CY2022	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	69965	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13645643	usd
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	521294	usd
CY2021	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	179267	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	125000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	139645	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1078015	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13064128	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	898748	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6506178	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-187496	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4356	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	191852	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6510534	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4356	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	3734446	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	186858	usd
CY2022	us-gaap	Notes Reduction NotesReduction	980233	usd
CY2021	HILS	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts	367384	usd
CY2021	HILS	Deferred Offering Costs Reclassified Against Common Stock And Additional Paidin Capital Upon Initial Public Offering DeferredOfferingCostsReclassifiedAgainstCommonStockAndAdditionalPaidinCapitalUponInitialPublicOffering	58091	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6900000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6600000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15400000	usd
CY2021Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-26.4
CY2022	HILS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	980075	shares
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zFS4AjOuZlS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zqizMqGlhQW5">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: valuation of common shares and stock options prior to the IPO, allowances of deferred tax assets, valuation of debt related instruments, and cash flow assumptions regarding going concern considerations. Although management believes the estimates that have been used are reasonable, actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zoKbg4JQ5In9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zahmEQknksX8">Concentration of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances with various financial institutions. Account balances at these institutions are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_90B_eus-gaap--FederalDepositInsuranceCorporationPremiumExpense_c20220101__20221231_zTP2ULd94Oe9" title="Federal deposit">250,000</span> per depositor. At various times during the year, bank account balances may have been in excess of federally insured limits. The Company has not experienced losses in such accounts. <span style="background-color: white">The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	61000	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	61000	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.38
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	240526	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.10
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14204	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.28
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1628813	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.34
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-26.4
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-26.4
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	1600000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	831000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	981908	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.69
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3734446	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1569003	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	2165443	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1392544	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	772899	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	2165443	usd
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	805000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1325288	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1325288	usd
CY2022	HILS	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Initial Embedded Redemption Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEmbeddedRedemptionValue	1487596	usd
CY2022	HILS	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue	-1832651	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	980233	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	980233	usd
CY2021	HILS	Change In Fair Value Of Redemption ChangeInFairValueOfRedemption	1800000	usd
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	1000000.0	shares
CY2022	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	90826	shares
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	70000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	675731	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.09
CY2021	HILS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	227737	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.76
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	903468	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.27
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1628813	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.34
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1628813	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	981908	shares
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	903468	shares
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	580642	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.945	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.040	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.113	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0169	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0339	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0060	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	7.03
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.70
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.48
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.25
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	5.47
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	800696	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1239269	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1900000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	the Company modified the stock option exercise price for stock options granted during 2020, increasing the exercise price of such stock options (after adjusting for the 1-for-26.4 reverse stock split) from $0.18 or $2.60 to $0.31 or $3.82 per share, respectively
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2300000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	652000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	1951000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	702000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	660000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	238000	usd
CY2022Q4	HILS	Deferred Tax Assets Operating Loss Carryforwards Capitalized Costs DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts	512000	usd
CY2021Q4	HILS	Deferred Tax Assets Operating Loss Carryforwards Capitalized Costs DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedCosts	394000	usd
CY2022Q4	HILS	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	163000	usd
CY2021Q4	HILS	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	178000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	81000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	45000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	534000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	336000	usd
CY2021Q4	HILS	Deferred Tax Assets Tax Deferred Expense Accrued Expenses And Other DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther	-66000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3901000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1827000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3901000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1827000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1779000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-463000	usd
CY2022	HILS	Income Tax Reconciliation Permanent Differences And Other IncomeTaxReconciliationPermanentDifferencesAndOther	257000	usd
CY2021	HILS	Income Tax Reconciliation Permanent Differences And Other IncomeTaxReconciliationPermanentDifferencesAndOther	-61000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-515000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-118000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	76000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	40000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	40000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	30000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2073000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	652000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	3900000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	1800000	usd
CY2022	HILS	Upfront Payment UpfrontPayment	150000	usd
CY2022	HILS	Milestone Payment MilestonePayment	1000000	usd

Files In Submission

Name	View Source	Status
0001493152-23-007977-index-headers.html	Edgar Link	pending
0001493152-23-007977-index.html	Edgar Link	pending
0001493152-23-007977.txt	Edgar Link	pending
0001493152-23-007977-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex4-3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
hils-20221231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hils-20221231_cal.xml	Edgar Link	unprocessable
hils-20221231_def.xml	Edgar Link	unprocessable
hils-20221231_lab.xml	Edgar Link	unprocessable
hils-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
image_026.jpg	Edgar Link	pending
image_027.jpg	Edgar Link	pending
image_028.jpg	Edgar Link	pending
image_029.jpg	Edgar Link	pending
image_030.jpg	Edgar Link	pending
image_031.jpg	Edgar Link	pending
image_032.jpg	Edgar Link	pending
image_033.jpg	Edgar Link	pending
image_034.jpg	Edgar Link	pending
image_035.jpg	Edgar Link	pending
image_036.jpg	Edgar Link	pending
image_037.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THAR
Tharimmune, Inc. Stock $thar

2023 Q1 Form 10-K Financial Statement

#000149315223007977 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THAR Tharimmune, Inc. Stock $thar

2023 Q1 Form 10-K Financial Statement

#000149315223007977 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THAR
Tharimmune, Inc. Stock $thar